Robert (Bob) J. Fox, MD / Jiwon Oh, MD, PhD, FRCPC - BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.

BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

SupportThis activity is supported by an educational grant from Sanofi.

Disclosure information is available at the beginning of the video presentation.